TriSalus

Canaccord Genuity Acted as the Sole Placement Agent to TriSalus Life Sciences, Inc. on its $22.0 Million Private Placement

Canaccord Genuity is pleased to announce that on May 2, 2025, it completed a private placement of common stock for TriSalus Life Sciences, Inc. (NASDAQ: TLSI) (the “Company”). The private placement comprised of 5,500,000 shares of the Company’s common stock at a purchase price of $4.00 per share, resulting in gross proceeds of $22.0 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. In conjunction with the private placement, the Company committed to a preferred stock exchange to simplify the capital structure.

The private placement was led by Nantahala Capital and included investments by Broadfin Holdings and additional healthcare-focused institutional investors. Canaccord Genuity acted as the sole placement agent for the offering.
    
TriSalus Life Sciences, Inc. is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.